By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.




CEO: Ed Kaye, M.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT


Company News
Sarepta (SRPT)’s Exondys 51 Saga Continues as More Details About FDA’s Criticism Uncovered 8/22/2017 6:17:53 AM
FDA Docs Reveal CDER Chief Skirted Procedures Approving Sarepta (SRPT)'s Controversial Drug Eteplirsen 8/3/2017 8:21:17 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 8/1/2017 1:13:11 PM
Sarepta (SRPT) Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications 7/27/2017 11:00:35 AM
Sarepta (SRPT) Announces Pricing Of $325 Million Public Offering Of Common Stock 7/25/2017 1:10:12 PM
Sarepta (SRPT) Announces Proposed $250 Million Public Offering Of Common Stock 7/24/2017 11:06:38 AM
Sarepta (SRPT) Secures $100 Million In Debt Financing 7/19/2017 11:15:38 AM
Clinigen And Sarepta (SRPT) Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 7/19/2017 7:48:15 AM
Sarepta (SRPT) And BioMarin (BMRN) Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation 7/18/2017 6:39:00 AM
New Sarepta (SRPT) CEO's M&A Experience Sparks Sale Speculation 6/30/2017 6:14:16 AM